




**Supplementary Figure 1 Forest plot of subgroup analysis among patients with elevated carbohydrate antigen 19-9 levels.** BUN: Blood urea nitrogen; CEA: Carcinoembryonic antigen; OR: Odds ratio; CI: Confidence interval.




**Supplementary Figure 2 Forest plot of sensitivity analysis incorporating bilirubin levels into the multivariable logistic regression model.** BUN: Blood urea nitrogen; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; DBIL: Direct bilirubin; CI: Confidence interval; OR: Odds ratio.

**Supplementary Table 1 Clinicopathological characteristics of the 33 patients with occult pancreatic ductal adenocarcinoma**

| No. | Admission | EUS-FNA | T | N | M | Location |
|---|---|---|---|---|---|---|
| 1 | 2020/10/22 | No | 1 | 0 | 0 | Tail |
| 2 | 2014/8/12 | No | 1c | 0 | 0 | Head |
| 3 | 2015/7/14 | No | 2 | 0 | 0 | Head |
| 4 | 2016/8/8 | No | 3 | 0 | 0 | Head |
| 5 | 2016/5/3 | No | 1 | 0 | 0 | Head |
| 6 | 2016/11/28 | No | 3 | 0 | 0 | Head |
| 7 | 2016/8/22 | No | 3 | 0 | 0 | Head |
| 8 | 2018/8/28 | No | 2 | 1 | 0 | Head |
| 9 | 2018/12/3 | No | 2 | 0 | 0 | Head |
| 10 | 2018/12/7 | No | 2 | 0 | 0 | Head |
| 11 | 2018/11/14 | No | 3 | 0 | 0 | Head |
| 12 | 2019/1/14 | No | 3 | 1 | 0 | Head |
| 13 | 2020/2/26 | No | 3 | 2 | 0 | Head |
| 14 | 2020/10/8 | No | 3 | 0 | 0 | Head |
| 15 | 2020/10/28 | No | 2 | 1 | 0 | Head |
| 16 | 2020/12/1 | No | 2 | 1 | 0 | Head |
| 17 | 2021/11/29 | Yes | 3 | x | 0 | Head |
| 18 | 2021/12/8 | No | 2 | 0 | 0 | Head |
| 19 | 2021/5/31 | No | 1 | 0 | 0 | Head |
| 20 | 2022/8/20 | No | 3 | 0 | 0 | Head |
| 21 | 2022/7/29 | No | 3 | 1 | 0 | Head |
| 22 | 2022/3/11 | No | 3 | 0 | 0 | Head |
| 23 | 2022/5/23 | Yes | 1b | x | 0 | Head |
| 24 | 2023/4/26 | Yes | 1 | x | 0 | Tail |
| 25 | 2023/4/15 | No | 3 | 0 | 0 | Body |
| 26 | 2023/10/7 | No | 1c | 0 | 0 | Head |
| 27 | 2023/8/8 | No | 1 | 0 | 0 | Head |
| 28 | 2023/3/21 | No | 1 | 0 | 0 | Head |

| | | | | | | |
|---|---|---|---|---|---|---|
| 29 | 2023/1/29 | No | 2 | 0 | 0 | Tail |
| 30 | 2023/6/5 | No | 2 | 0 | 0 | Tail |
| 31 | 2023/3/28 | No | 3 | 1 | 0 | Tail |
| 32 | 2023/8/9 | No | 3 | 0 | 0 | Head |
| 33 | 2023/4/10 | Yes | 1c | x | 0 | Head |

EUS-FNA: Endoscopic ultrasound-guided fine-needle aspiration. "x" denotes unknown N stage due to EUS-FNA alone without lymphoid tissue acquisition.

**Supplementary Table 2 Distribution of missing data across study variables**

| **Variables** | **Missing data** |
|---|---|
| Age | 0 |
| Sex | 0 |
| Atrophy | 0 |
| Mass | 0 |
| Parenchymal calcification | 0 |
| Stone | 0 |
| Cyst | 0 |
| Duration | 0 |
| Jaundice | 0 |
| Abdominal pain | 0 |
| Acute pancreatitis | 0 |
| Diabetes mellitus | 0 |
| Hypertension | 0 |
| Smoking index | 0 |
| Drinking | 0 |
| ALB | 0 |
| TP | 0 |
| DBIL | 0 |
| ALT | 0 |
| AST | 0 |
| Ionized calcium | 0 |

| | |
|---|---|
| PLT | 2 (0.6%) |
| LYM | 2 (0.6%) |
| WBC | 2 (0.6%) |
| HGB | 2 (0.6%) |
| HCT | 2 (0.6%) |
| DD | 3 (0.9%) |
| FIB | 3 (0.9%) |
| INR | 3 (0.9%) |
| PT | 3 (0.9%) |
| CRE | 4 (1.1%) |
| BUN | 4 (1.1%) |
| MPV | 7 (2.0%) |
| Weight loss | 9 (2.6%) |
| GLU | 19 (5.4%) |
| CA19-9 | 21 (6.0%) |
| BMI | 29 (8.3%) |
| CEA | 33 (9.4%) |
| CA125 | 50 (14.2%) |
| Amylase | 103 (29.3%) |
| Lipase | 151 (43.0%) |
| CA242 | 165 (47.1%) |
| IgG4 | 222 (63.2%) |
| Glycosylated hemoglobin | 260 (74.1%) |

ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; BUN: Blood urea nitrogen; CA19-9: Carbohydrate antigen 19-9; CA125: Carbohydrate antigen 125; CA242: Carbohydrate antigen 242; CEA: Carcinoembryonic antigen; CRE: Creatinine; DBIL: Direct bilirubin; DD: D-dimer; FIB: Fibrinogen; GLU: Glucose; HCT: Hematocrit; HGB: Hemoglobin; IgG4: Immunoglobulin G subclass 4; INR: International normalized ratio; LYM: Lymphocyte; MPV: Mean platelet volume; PLT: Platelet; PT: Prothrombin time; RBC: Red blood cell; TP: Total protein; WBC: White blood cell.

**Supplementary Table 3 Variance inflation factor analysis for multicollinearity assessment**

| Variables | VIF |
|---|---|
| Age | 1.343 |
| BMI | 1.171 |
| Sex | 1.410 |
| Atrophy | 1.193 |
| Mass | 1.307 |
| Parenchymal calcification | 1.258 |
| Stone | 1.398 |
| Duration | 1.208 |
| Cyst | 1.166 |
| Jaundice | 1.658 |
| Abdominal pain | 1.174 |
| Weight loss | 1.119 |
| Acute pancreatitis | 1.163 |
| Diabetes mellitus | 1.326 |
| Hypertension | 1.145 |
| Smoking index | 1.177 |
| Drinking | 1.187 |
| MPV | 1.345 |
| PLT | 1.459 |
| LYM | 1.247 |
| WBC | 1.272 |
| HGB | 2.965 |
| HCT | 2.853 |
| GLU | 1.350 |
| CRE | 1.297 |
| BUN | 1.212 |
| ALB | 2.174 |

| | |
|---|---|
| TP | 1.868 |
| DBIL | 1.658 |
| ALT | 2.165 |
| AST | 2.084 |
| Ionized calcium | 1.223 |
| DD | 1.154 |
| FIB | 1.291 |
| INR | 2.004 |
| PT | 2.124 |
| CA19-9 | 1.227 |
| CA125 | 1.164 |
| CEA | 1.315 |

ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; BUN: Blood urea nitrogen; CA19-9: Carbohydrate antigen 19-9; CA125: Carbohydrate antigen 125; CA242: Carbohydrate antigen 242; CEA: Carcinoembryonic antigen; CRE: Creatinine; DBIL: Direct bilirubin; DD: D-dimer; FIB: Fibrinogen; GLU: Glucose; HCT: Hematocrit; HGB: Hemoglobin; INR: International normalized ratio; LYM: Lymphocyte; MPV: Mean platelet volume; PLT: Platelet; PT: Prothrombin time; TP: Total protein; VIF: Variance inflation factor; WBC: White blood cell.

**Supplementary Table 4 Baseline demographic, clinical, imaging, and laboratory characteristics after multiple imputation**

| **Characteristics** | | **Overall** *n* **= 359** | **Non-PDAC** *n* **= 326** | **CP-PDAC** *n* **= 33** | ***P*** |
|---|---|---|---|---|---|
| Age in years, median [Q1, Q3] | | 52 [42, 61] | 52 [41, 60] | 54 [48, 62] | 0.256 |
| BMI in $kg/m^2$, median [Q1, Q3] | | 21.09 [19.32, 22.56] | 21.09 [19.29, 22.58] | 21.06 [19.37, 22.49] | 0.973 |
| Sex, % | Female | 74 (20.61) | 67 (20.55) | 7 (21.21) | 1.000 |
| | Male | 285 (79.39) | 259 (79.45) | 26 (78.79) | |
| Imaging features, % | | | | | |
| Atrophy | No | 304 (84.68) | 278 (85.28) | 26 (78.79) | 0.464 |
| | Yes | 55 (15.32) | 48 (14.72) | 7 (21.21) | |
| Mass | No | 224 (62.40) | 210 (64.42) | 14 (42.42) | 0.022 |
| | Yes | 135 (37.60) | 116 (35.58) | 19 (57.58) | |
| Parenchymal calcification | No | 235 (65.46) | 212 (65.03) | 23 (69.70) | 0.73 |
| | Yes | 124 (34.54) | 114 (34.97) | 10 (30.30) | |
| Stone | No | 198 (55.15) | 173 (53.07) | 25 (75.76) | 0.021 |
| | Yes | 161 (44.85) | 153 (46.93) | 8 (24.24) | |
| Cyst | No | 285 (79.39) | 260 (79.75) | 25 (75.76) | 0.753 |

| | | | | | |
|---|---|---|---|---|---|
| | Yes | 74 (20.61) | 66 (20.25) | 8 (24.24) | |
| Clinical features | | | | | |
| Duration in days, median [Q1, Q3] | | 31 [13, 153] | 31 [13, 168] | 28 [10, 91] | 0.115 |
| Jaundice, % | No | 271 (75.49) | 250 (76.69) | 21 (63.64) | 0.147 |
| | Yes | 88 (24.51) | 76 (23.31) | 12 (36.36) | |
| Abdominal pain, % | No | 110 (30.64) | 103 (31.60) | 7 (21.21) | 0.301 |
| | Yes | 249 (69.36) | 223 (68.40) | 26 (78.79) | |
| Weight loss, % | No | 210 (58.50) | 193 (59.20) | 17 (51.52) | 0.504 |
| | Yes | 149 (41.50) | 133 (40.80) | 16 (48.48) | |
| Acute pancreatitis, % | No | 292 (81.34) | 266 (81.60) | 26 (78.79) | 0.873 |
| | Yes | 67 (18.66) | 60 (18.40) | 7 (21.21) | |
| Diabetes mellitus, % | No | 292 (81.34) | 267 (81.90) | 25 (75.76) | 0.529 |
| | Yes | 67 (18.66) | 59 (18.10) | 8 (24.24) | |
| Hypertension, % | No | 302 (84.12) | 275 (84.36) | 27 (81.82) | 0.896 |
| | Yes | 57 (15.88) | 51 (15.64) | 6 (18.18) | |
| Smoking index, % | 0 | 193 (53.76) | 175 (53.68) | 18 (54.55) | 0.696 |

| | | | | | |
|---|---|---|---|---|---|
| | < 400 | 63 (17.55) | 59 (18.10) | 4 (12.12) | |
| | 400–799 | 66 (18.38) | 60 (18.40) | 6 (18.18) | |
| | ≥ 800 | 37 (10.31) | 32 (9.82) | 5 (15.15) | |
| Drinking, % | None | 259 (72.14) | 233 (71.47) | 26 (78.79) | 0.668 |
| | Moderate | 41 (11.42) | 38 (11.66) | 3 (9.09) | |
| | Heavy | 59 (16.43) | 55 (16.87) | 4 (12.12) | |
| Laboratory test | | | | | |
| MPV in fL, median [Q1, Q3] | | 11.1 [10.1, 12.2] | 11.1 [10.1, 12.2] | 11.1 [10.0, 12.5] | 0.524 |
| PLT as × $10^9$/L, median [Q1,Q3] | | 197 [156, 251] | 198 [156, 251] | 193 [146, 251] | 0.733 |
| LYM as × $10^9$/L, median [Q1,Q3] | | 1.42 [1.07, 1.85] | 1.42 [1.10, 1.87] | 1.20 [1.04, 1.58] | 0.170 |
| WBC as × $10^9$/L, median [Q1,Q3] | | 5.69 [4.62, 7.23] | 5.70 [4.60, 7.22] | 5.62 [5.01, 7.51] | 0.522 |
| HGB in g/L, median [Q1, Q3] | | 132 [119, 142] | 132 [120, 142] | 126 [111, 139] | 0.154 |

| | | | | |
|---|---|---|---|---|
| HCT as %, mean [SD] | 39.8 [5.44] | 40.0 [5.36] | 38.0 [5.94] | 0.046 |
| RBC as × $10^9$/L, mean [Q1,Q3] | 4.26 [0.59] | 4.28 [0.58] | 4.07 [0.62] | 0.050 |
| GLU in mmol/L, median [Q1, Q3]) | 5.58 [4.90, 6.72] | 5.58 [4.92, 6.71] | 5.64 [4.76, 7.22] | 0.880 |
| CRE in μmol/L, median [Q1,Q3] | 53.0 [45.0, 62.0] | 53.0 [45.0, 62.0] | 53.0 [48.0, 64.0] | 0.657 |
| BUN in mmol/L, median [Q1, Q3] | 4.71 [3.79, 5.96] | 4.69 [3.79, 5.91] | 5.49 [4.16, 7.09] | 0.051 |
| ALB in g/L, mean [SD] | 39.04 [5.82] | 39.06 [5.81] | 38.93 [5.93] | 0.904 |
| TP in g/L, mean [SD] | 66.88 [8.51] | 66.98 [8.55] | 65.97 [8.20] | 0.517 |
| DBIL in μmol/L, median [Q1, Q3] | 5.30 [3.40, 16.10] | 5.30 [3.40, 12.80] | 7.60 [4.00, 111.40] | 0.062 |
| ALT in U/L, median [Q1, Q3] | 34.00 [20.00, 86.00] | 32.50 [19.00, 83.75] | 56.00 [27.00, 98.00] | 0.019 |
| AST in U/L, median [Q1, Q3] | 27.00 [19.00, 59.00] | 26.00 [19.00, 57.00] | 30.00 [22.00, 66.00] | 0.166 |

| | | | | |
|---|---|---|---|---|
| Ionized calcium in mmol/L, median [Q1, Q3] | 2.20 [2.11, 2.32] | 2.19 [2.10, 2.32] | 2.27 [2.19, 2.31] | 0.077 |
| DD in mg/L, median [Q1, Q3] | 0.64 [0.44, 1.04] | 0.65 [0.44, 1.05] | 0.50 [0.42, 1.00] | 0.711 |
| FIB in g/L, median [Q1, Q3] | 3.48 [2.79, 4.23] | 3.47 [2.79, 4.22] | 3.73 [2.82, 4.26] | 0.410 |
| INR, median [Q1, Q3] | 1.03 [0.97, 1.09] | 1.03 [0.97, 1.09] | 1.03 [0.98, 1.08] | 0.956 |
| PT in seconds, median [Q1, Q3] | 12.9 [11.9, 13.8] | 12.9 [11.9, 13.8] | 12.9 [12.0, 14.0] | 0.490 |
| CA19-9 in U/mL, median [Q1, Q3] | 22.87 [10.16, 73.40] | 21.24 [9.65, 58.01] | 186.20 [39.27, 789.40] | < 0.001 |
| CA125 in U/mL, median [Q1, Q3] | 15.30 [10.25, 24.01] | 14.60 [10.03, 23.52] | 21.00 [12.70, 35.51] | 0.017 |
| CEA in ng/mL, median [Q1, Q3] | 2.56 [1.67, 3.45] | 2.47 [1.61, 3.24] | 3.69 [2.78, 6.65] | < 0.001 |

ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; BUN: Blood urea nitrogen; CA19-9: Carbohydrate antigen 19-9; CA125: Carbohydrate antigen 125; CA242: Carbohydrate antigen 242; CEA: Carcinoembryonic antigen; CRE: Creatinine; DBIL: Direct bilirubin; DD: D-dimer; FIB: Fibrinogen; GLU: Glucose; HCT: Hematocrit;

HGB: Hemoglobin; INR: International normalized ratio; LYM: Lymphocyte; MPV: Mean platelet volume; PLT: Platelet; PT: Prothrombin time; TP: Total protein; WBC: White blood cell.

**Supplementary Table 5 Least absolute shrinkage and selection operator regression coefficients of variables selected for multivariable analysis**

| Variables | LASSO regression coefficient |
|---|---|
| Pancreatic mass | 0.254 |
| Main pancreatic duct stones | −0.202 |
| BUN | 0.133 |
| Serum ionized calcium | 0.035 |
| CA19-9 | 0.630 |
| CEA | 0.197 |

BUN: Blood urea nitrogen; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; LASSO: Least absolute shrinkage and selection operator.

**Supplementary Table 6 Baseline characteristics of patients with elevated carbohydrate antigen 19-9 levels**

| Characteristics | | Overall<br>*n* = 134 | Non-PDAC<br>*n* = 109 | CP-PDAC<br>*n* = 25 | *P* |
|---|---|---|---|---|---|
| Age in years, median [Q1, Q3] | | 55 [48, 63] | 56 [48, 63] | 51 [48, 58] | 0.281 |
| BMI in kg/m$^2$, median [Q1, Q3] | | 21.06 [19.41, 22.49] | 21.09 [19.53, 22.66] | 20.76 [19.37, 22.22] | 0.654 |
| Sex, % | Female | 20 (14.93) | 16 (14.68) | 4 (16.00) | 1 |
| | Male | 114 (85.07) | 93 (85.32) | 21 (84.00) | |
| Imaging features, % | | | | | |
| Atrophy | No | 120 (89.55) | 99 (90.83) | 21 (84.00) | 0.52 |
| | Yes | 14 (10.45) | 10 (9.17) | 4 (16.00) | |
| Mass | No | 71 (52.99) | 59 (54.13) | 12 (48.00) | 0.74 |
| | Yes | 63 (47.01) | 50 (45.87) | 13 (52.00) | |
| Parenchymal calcification | No | 97 (72.39) | 82 (75.23) | 15 (60.00) | 0.198 |
| | Yes | 37 (27.61) | 27 (24.77) | 10 (40.00) | |
| Stone | No | 94 (70.15) | 75 (68.81) | 19 (76.00) | 0.641 |
| | Yes | 40 (29.85) | 34 (31.19) | 6 (24.00) | |
| Cyst | No | 108 (80.60) | 90 (82.57) | 18 (72.00) | 0.355 |

| | | | | | |
|---|---|---|---|---|---|
| | Yes | 26 (19.40) | 19 (17.43) | 7 (28.00) | |
| Clinical features | | | | | |
| Duration in days, median [Q1, Q3] | | 30 [11, 91] | 30 [11, 92] | 30 [10, 91] | 0.429 |
| Jaundice, % | No | 74 (55.22) | 59 (54.13) | 15 (60.00) | 0.757 |
| | Yes | 60 (44.78) | 50 (45.87) | 10 (40.00) | |
| Abdominal pain, % | No | 46 (34.33) | 41 (37.61) | 5 (20.00) | 0.15 |
| | Yes | 88 (65.67) | 68 (62.39) | 20 (80.00) | |
| Weight loss, % | No | 73 (54.48) | 62 (56.88) | 11 (44.00) | 0.345 |
| | Yes | 61 (45.52) | 47 (43.12) | 14 (56.00) | |
| Acute pancreatitis, % | No | 112 (83.58) | 92 (84.40) | 20 (80.00) | 0.813 |
| | Yes | 22 (16.42) | 17 (15.60) | 5 (20.00) | |
| Diabetes mellitus, % | No | 108 (80.60) | 89 (81.65) | 19 (76.00) | 0.716 |
| | Yes | 26 (19.40) | 20 (18.35) | 6 (24.00) | |
| Hypertension, % | No | 109 (81.34) | 88 (80.73) | 21 (84.00) | 0.926 |
| | Yes | 25 (18.66) | 21 (19.27) | 4 (16.00) | |
| Smoking index, % | 0 | 70 (52.24) | 55 (50.46) | 15 (60.00) | 0.863 |
| | < 400 | 19 (14.18) | 16 (14.68) | 3 (12.00) | |
| | 400–799 | 26 (19.40) | 22 (20.18) | 4 (16.00) | |

| | | | | | |
|---|---|---|---|---|---|
| | ≥ 800 | 19 (14.18) | 16 (14.68) | 3 (12.00) | |
| Drinking, % | None | 100 (74.63) | 79 (72.48) | 21 (84.00) | 0.39 |
| | Moderate | 15 (11.19) | 14 (12.84) | 1 (4.00) | |
| | Heavy | 19 (14.18) | 16 (14.68) | 3 (12.00) | |
| Laboratory test | | | | | |
| MPV in fL, median [Q1, Q3] | | 11.60 [10.30, 12.60] | 11.60 [10.30, 12.60] | 11.10 [10.50, 12.80] | 0.756 |
| PLT as × $10^9$/L, median [Q1,Q3] | | 188.00 [147.00, 248.75] | 189.00 [147.00, 246.00] | 187.00 [146.00, 251.00] | 0.97 |
| LYM as × $10^9$/L, median [Q1,Q3] | | 1.33 [1.04, 1.80] | 1.32 [1.06, 1.85] | 1.33 [1.01, 1.55] | 0.475 |
| WBC as × $10^9$/L, median [Q1,Q3] | | 5.62 [4.65, 7.70] | 5.54 [4.58, 7.62] | 6.15 [5.36, 8.03] | 0.286 |
| HGB in g/L, median [Q1, Q3] | | 128.50 [114.25, 139.00] | 128.00 [115.00, 139.00] | 132.00 [111.00, 142.00] | 0.871 |
| HCT as %, median [Q1, Q3] | | 39.50 [35.32, 42.10] | 39.60 [35.40, 42.10] | 39.20 [33.00, 42.60] | 0.782 |
| RBC as × $10^9$/L, median [Q1,Q3] | | 4.12 [3.80, 4.58] | 4.12 [3.82, 4.56] | 4.12 [3.45, 4.68] | 0.704 |

| | | | | |
|---|---|---|---|---|
| GLU as mmol/L, median [Q1,Q3] | 5.99 [5.23, 7.21] | 6.04 [5.30, 7.29] | 5.46 [4.76, 6.66] | 0.164 |
| CRE in μmol/L, median [Q1,Q3] | 52.50 [45.25, 61.90] | 53.00 [44.00, 61.00] | 52.00 [48.00, 64.00] | 0.451 |
| BUN as mmol/L, median [Q1,Q3] | 4.72 [3.77, 6.21] | 4.69 [3.77, 6.00] | 5.85 [4.55, 7.58] | 0.023 |
| ALB in g/L, median [Q1, Q3] | 37.35 [34.30, 41.85] | 37.20 [34.30, 41.18] | 37.60 [35.30, 42.80] | 0.442 |
| TP in g/L, median [Q1, Q3] | 66.20 [61.30, 73.20] | 66.20 [61.30, 73.30] | 64.80 [60.90, 72.50] | 0.797 |
| DBIL in μmol/L, median [Q1,Q3] | 12.60 [4.05, 96.27] | 12.80 [4.00, 86.70] | 12.00 [4.30, 124.20] | 0.802 |
| ALT in U/L, median [Q1, Q3] | 69.50 [25.00, 190.75] | 70.00 [25.00, 225.00] | 58.00 [27.00, 154.00] | 0.916 |
| AST in U/L, median [Q1, Q3] | 49.00 [22.25, 120.25] | 53.00 [22.00, 122.00] | 41.00 [23.00, 77.00] | 0.482 |
| Ionized calcium as mmol/L, median [Q1,Q3] | 2.19 [2.12, 2.32] | 2.18 [2.11, 2.31] | 2.25 [2.16, 2.34] | 0.137 |
| DD in mg/L, | 0.73 [0.50, 1.11] | 0.71 [0.54, 1.11] | 0.76 [0.43, 1.05] | 0.644 |

| | | | | |
|---|---|---|---|---|
| median [Q1, Q3] | | | | |
| FIB in g/L, median [Q1, Q3] | 3.88 [3.14, 4.71] | 3.88 [3.22, 4.74] | 3.87 [2.84, 4.53] | 0.429 |
| INR, median [Q1, Q3] | 1.02 [0.97, 1.09] | 1.02 [0.96, 1.09] | 1.02 [0.98, 1.08] | 0.799 |
| PT in seconds, median [Q1, Q3] | 12.90 [12.12, 13.88] | 12.90 [12.20, 13.80] | 12.90 [12.00, 14.20] | 0.607 |
| CA125, median [Q1, Q3] | 19.63 [12.62, 29.46] | 18.72 [12.60, 28.30] | 23.38 [12.70, 39.02] | 0.268 |
| CEA, median [Q1, Q3] | 3.13 [2.44, 4.43] | 3.08 [2.35, 4.16] | 4.86 [2.98, 6.92] | 0.015 |

ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; BUN: Blood urea nitrogen; CA19-9: Carbohydrate antigen 19-9; CA125: Carbohydrate antigen 125; CA242: Carbohydrate antigen 242; CEA: Carcinoembryonic antigen; CP: Chronic pancreatitis; CRE: Creatinine; DBIL: Direct bilirubin; DD: D-dimer; FIB: Fibrinogen; GLU: Glucose; HCT: Hematocrit; HGB: Hemoglobin; INR: International normalized ratio; LYM: Lymphocyte; MPV: Mean platelet volume; PDAC: Pancreatic ductal adenocarcinoma; PLT: Platelet; PT: Prothrombin time; TP: Total protein; WBC: White blood cell.